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did not pay for their prescriptions were signiﬁcantly different 
(p < 0.05). The average anti-diabetic drug cost of the patients
who paid out-of-pocket was 643.38 Baht ($US 1 = 40Baht) and
their average total drug cost was 1853.12 Baht, while the average
anti-diabetic drug cost of the patients who did not pay for their
prescriptions was 437.91 Baht and their average total drug cost
was 990.94 Baht. In drug cost per day basis, the results showed
that the average anti-diabetic drug costs per day between two
patient groups were not signiﬁcantly different (p > 0.05).
However, their average total drug costs per day were signiﬁcantly
different (p < 0.05). The average total drug cost per day of the
patients who paid out-of-pocket was 26.76 Baht, while it was
17.56 Baht for the patients who did not pay for their prescrip-
tions. Linear regression results showed that the patient’s type of
payment signiﬁcantly inﬂuenced both anti-diabetic and total
drug cost per prescription and cost per day. CONCLUSIONS: A
signiﬁcant relationship between patient’s payment type and pre-
scription drug costs for diabetic patients was found. The patients
who paid out-of-pocket likely obtained more expensive pre-
scription drugs than did the patients who did not pay for their
prescriptions.
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OBJECTIVE: To examine prescribing trends of combination oral
hypoglycemic therapy for persons with Type-II diabetes using
prescription claims. METHODS: Prescribing trends were identi-
ﬁed for patients using combination oral hypoglycemic agents for
the treatment of diabetes during a three month period beginning
November, 2003–January, 2004. Persons were considered newly
treated with type II diabetes if there were no prescription claims
for insulin or oral diabetes agents during a three month period
prior to the ﬁrst prescription for a combination product. Trends
in patients already receiving oral hypoglycemic agents or insulin
were identiﬁed if combination therapy was added after mini-
mally three months of therapy or if oral hypoglycemic combi-
nation therapy was added to an existing treatment regimen
during the three-month observation period. Current recommen-
dations for use of combination therapy were compared to the
results of prescribing trends obtained from administrative data.
RESULTS: On average, approximately 661,811 persons were
identiﬁed with combination therapy on a monthly basis (211,922
in November, 2003; 227,981 in December, 2003; 221,908 in
January, 2004). Of these, on average approximately 130,708
received metformin/rosiglitazone, 491,380 received metformin/
glyburide, and 38,011 received metformin/glipizide. Several pre-
scribing trends were observed for these agents. Despite literature
to the contrary, the combination metformin/rosiglitazone was
prescribed as initial therapy for 19% of patients receiving pre-
scriptions for that product. Combination products were pre-
scribed as initial therapy for 11% to 19% of patients depending
on product. Almost 1% of patients received a combination
product plus two or more agents on a monthly basis. A small
number of patients received two combination products in their
daily regimen. CONCLUSION: Approximately one-ﬁfth of
patients receive initial oral hypoglycemic therapy outside of
current prescribing recommendations. The prescribing patterns
observed from this data suggest the need for treatment regimen
management and for plans to carefully study the economic
impact of multiple regimen treatments.
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Objective: To quantify the incidence and risk of needlestick
injury (NI) in nurses caring for patients with diabetes.
METHODS: Four hundred nurses caring for patients with dia-
betes in 381 hospitals throughout the United States reported data
on their experience with NI, focusing on those occurring within
the past year. If respondents experienced multiple NI during this
period, detailed data were collected on the most recent event.
RESULTS: Of the 400 nurses, 313 (78.3%) reported having ever
had a NI, 110 (27.5%) reported having had a NI within the last
twelve months, and 44 (40% of those 110) reported multiple NI.
Nearly two-thirds of these injuries (n = 73; 66.4%) were punc-
tures that drew blood, resulting in one case of contracted hepati-
tis C. The cumulative annual incidence of NI events was 448 NI
per 1000 nurses. Nurses reported the injury in adherence with
existing policies in 21.8% of cases. Disposable syringes were
involved in 88 (80%) of the events. In half of the injuries (n =
55), the needled device was equipped with a safety feature that
was ineffective, primarily because it was not fully activated (n =
47; 85.5%) or it malfunctioned (n = 2 to 5; 3.6% to 9.1%). NI
most commonly occurred while nurses were injecting insulin 
(n = 33; 30%). In the two weeks following their NI, 60.1% of
nurses were more afraid of needled devices than before the injury
and 41.8% felt anxious, depressed, or stressed. As a direct result
of the NI, nurses missed 77 days of work. CONCLUSIONS: This
study is the ﬁrst to show the relatively high risk both of NI and
of NI that draws blood among nurses injecting insulin with a
disposable syringe. Additionally, this study reveals signiﬁcant
post-NI emotional distress, suggests signiﬁcant under-reporting
of NI to hospital ofﬁcials, and demonstrates the need for a more
effective needle safety device.
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OBJECTIVE: For patients with type-1 diabetes, having a pre-
ferred insulin delivery system may lead to better compliance and
better clinical and patient-reported outcomes. The purpose of
this study was to assess the reliability and validity of the Insulin
Delivery System Questionnaire (IDSQ), an instrument developed
to measure overall insulin satisfaction and preference for an
insulin delivery system. METHODS: The IDSQ was adminis-
tered to 137 patients with type-1 diabetes at screening, baseline,
crossover, and endpoint of a randomized, noninferiority,
crossover trial designed to compare the glycemic control of
injectable vs. inhaled insulin. Psychometric analyses included
internal consistency (Cronbach’s alpha), factorial validity (prin-
cipal component analysis with Promax rotation), discriminant
validity (ANCOVA model with baseline score and other covari-
ates), and responsiveness (t-tests). RESULTS: Exploratory factor
analysis indicated that there were three factors accounting for
73% of the variance. All items loaded above >0.50 on either
Factor one, lifestyle impact; Factor two, ease of dosing; or Factor
three, satisfaction/preference with the exception of the “easy to
control my blood sugar” (BG) item. Cronbach’s alpha coefﬁ-
cients calculated for the factors were 0.93, 0.86, and 0.86,
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respectively. Each of the three factors and the BG item discrim-
inated between those patients who preferred inhaled insulin and
those who preferred injectable insulin (all p < 0.001). Factors
one and three and the BG item demonstrated the ability to detect
change from baseline (injectable treatment) to following treat-
ment with inhaled insulin (all p < 0.001). Factor analysis and
interscale correlations indicated that the 16 items could be
summed to a total IDSQ score. Cronbach’s alpha for the total
score was 0.93. CONCLUSION: The IDSQ is a reliable and
valid instrument to assess insulin delivery system satisfaction in
patients with type-1 diabetes.
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OBJECTIVES: Public health education is a cornerstone in
primary prevention of diabetes mellitus (DM). However, valid
and reliable tools to evaluate outcomes of DM education among
the general public are lacking. We aim to evaluate the reliability
and validity of the General Diabetes Knowledge Test (GDKT)
for use among subjects with and without DM. METHODS: The
GDKT is a 36-item questionnaire (range 0–100) constructed
based on existing public DM education materials and covers six
content areas: overview, risk factors, symptoms, complications,
management and monitoring (for both Type-1 and 2 DM). To
achieve wide representation, English-speaking subjects (aged >
21) were recruited by convenience sampling at a public health
promotion event. The GDKT was ﬁrst administered to 54 DM
and 42 non-DM subjects. Eighteen subjects voluntarily partici-
pated in retest (all were DM). Internal consistency of GDKT was
assessed using Kuder-Richardson Formula 20 (KRF20). Item dif-
ﬁculty was assessed by calculating the ratio of number of correct
answers to number of respondents, range 0.00 (most difﬁcult) to
1.00 (least difﬁcult) and compared between DM and non-DM
subjects using Students’ t-test. Test-retest reliability was assessed
using intraclass correlation coefﬁcient (ICC). Construct validity
was assessed using a known-group approach where DM subjects
were expected to have higher GDKT scores than non-DM sub-
jects. RESULTS: Internal consistency of GDKT was high (KRF20
= 0.9289). Item difﬁculty ranged from 0.59–0.97 and was sig-
niﬁcantly different (p < 0.05) between subjects with and without
DM for 8 items. Test-retest reliability was moderate (ICC = 0.54,
median = 94.4, range = 72.2–100.0, 95% CI: 0.77). Mean scores
at ﬁrst (91.8 ± 9.83) and second (93.3 ± 1.24) administrations
were not signiﬁcantly different (p = 0.38). As expected, DM sub-
jects reported better mean (±SD) GDKT scores (90.8 ± 11.35)
compared to non-DM subjects (85.7 ± 20.80) although the dif-
ference was not statistically signiﬁcant (p = 0.13). CONCLU-
SION: The internal consistency and construct validity of the
GDKT was demonstrated in this study.
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OBJECTIVES: The aim of this study was evaluate the long-term
costs and clinical outcomes of using either insulin aspart or
human insulin (HI) at mealtimes in patients with type-1 diabetes,
based on the clinical ﬁndings of a multicentre, randomized, open-
label comparative trial in 882 patients, which showed that mean
(±SEM) HbA1c was lower after 12 months with insulin aspart
than with HI (7.78 ± 0.03 versus 7.93 ± 0.05, P = 0.005).
METHODS: Long-term clinical and cost outcomes were esti-
mated using the CORE Diabetes Model, a peer-reviewed, vali-
dated model that employs standard Markov/Monte Carlo
simulation techniques to describe the incidence and progression
of diabetes-related complications. Transition probabilities were
derived from major clinical studies. Published country-speciﬁc
costs, health care resource utilization, clinical data and recom-
mended discount rates were used. A lifetime horizon and third
party payer perspective was taken (direct costs only). Extensive
sensitivity analyses were performed. RESULTS: Discounted
quality-adjusted life expectancy (QALE) was improved by 0.08
to 0.22 years with insulin aspart versus HI in the nine countries
investigated. Lifetime cost savings were observed with insulin
aspart in the Austrian, Dutch, French, and Norwegian settings.
Overall costs were increased with insulin aspart versus HI in
Denmark, Finland, Germany, Spain and Sweden, with incre-
mental cost-effectiveness ratios of DKK20,814, €4434, €9553,
€20,916 and SEK32,541 per QALY gained respectively. CON-
CLUSIONS: Improvements in glycemic control associated with
insulin aspart led to improved QALE due to reduced incidence
of complications versus HI. Insulin aspart was projected to be
either cost-saving or cost-effective compared to HI over patient
lifetimes according to accepted international thresholds.
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OBJECTIVES: Using claims data, develop a measure of vari-
ability in insulin use that could be used as a proxy measure of
non-adherence to insulin. Measure the effect of variability of
insulin use on total and diabetes-attributable health care costs in
a managed care population. METHODS: Using a large managed
care administrative claims database, all patients with a prescrip-
tion for long- or intermediate-acting insulin from January, 2000
through June, 2001 were selected (n = 12,336) from among con-
tinuously eligible patients age 18 years and older. Total insulin
units dispensed with each prescription were computed by multi-
plying quantity (ml) from the claims data and strength (units/ml)
from NDC reference data. Units-per-day were computed for each
prescription pair by dividing units dispensed by the number of
days until the next prescription. A time series of units-per-day
was created for each patient during a one year follow-up period.
